UNIVERSITY OF KONSTANZ IMAGE: FLUORESCENCE MICROSCOPY IMAGE OF TINTED MITOCHONDRIA CREDIT: NICOLA ROVERATO, UNIVERSITY OF KONSTANZ Parkinson’s disease is the second most common, age-related, neurodegenerative disease: In Germany alone, about 300,000 people are affected and experience sometimes major limitations to their quality of life. Although Parkinson’s is so widespread, there is still no treatment that...
OKAYAMA UNIVERSITY IMAGE: THE MEDIAN AGE GAP (APPARENT AGE ESTIMATED BY AI SOFTWARE MINUS REAL AGE) WAS HIGHER FOR PD PATIENTS THAN FOR HEALTHY SUBJECTS. CREDIT: 2021 BRAIN SUPPLEMENT Parkinson’s disease (PD) is a well-studied neurodegenerative disorder that affects between 7 and 10 million people worldwide. Despite PD being a recurrent topic in the medical...
AARHUS UNIVERSITY Parkinson’s disease has always been considered a brain disorder. However, new research reveals a close link between the disease and certain immune cells in the blood. Researchers from Aarhus University have taken the first step on a path which can lead to new ways of understanding and, in the long term, possibly treating this widespread disease...
by Osaka City University (A) The neuroprotection by sesaminol. ARE: antioxidant response element, EpRE: electrophile responsive element, ROS: reactive oxygen species, NQO1: NAD(P)H: quinone oxidoreductase, HO-1: hemo oxygenase-1, ?-GCS:??-glutamylcysteine synthetase(B) Effects of sesaminol and 6-OHDA on the viability of SH-SY5Y cells.SH-SY5Y cells were incubated with 0.25~10 ?g/ml of sesaminol for 2 h, followed by treatment...
Scientists from Skoltech and A.I. Burnazyan Federal Medical and Biophysical Center have designed and developed a second opinion system, based on AI-assisted video analysis, which can help medical professionals to objectively assess patients with Parkinson’s disease (PD) even at an early stage. This approach can help avoid misdiagnosing this disease, distinguishing between its stages, adjusting...
IOS PRESS Amsterdam, NL, February 3, 2021 – Patients with Parkinson’s disease (PD) and healthcare professionals caring for them have expressed concerns about the COVID-19 vaccine’s efficacy and safety in the specific context of PD and its symptomatic treatment. In a commentary just published in the Journal of Parkinson’s Disease, a set of experts addresses these concerns from...
by University of Iowa Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson’s disease. Credit: Wikipedia Taking a particular type of medication to treat enlarged prostate is associated with a reduced risk of developing Parkinson’s disease, according to a large observational study led by researchers at the University of Iowa,...
by University of Pennsylvania Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson’s disease. Credit: Wikipedia Many genetic mutations have been found to be associated with a person’s risk of developing Parkinson’s disease. Yet for most of these variants, the mechanism through which they act remains unclear. Now...
by Nagoya University Parkinson’s disease (PD) is a neurodegenerative disorder caused by the loss of dopaminergic neurons and characterized by motor signs including bradykinesia, rigidity, resting tremor, and reduced postural reflex. More than 50% of dopaminergic neurons in the substantia nigra are lost at the onset of motor symptoms in PD. Prodromal symptoms, such as dysautonomia,...
by American Associates, Ben-Gurion University of the Negev Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson’s disease. Credit: Wikipedia Ben-Gurion University of the Negev researchers have discovered that the protein BMP5/7 offers promising therapeutics that could slow down or halt the progression of Parkinson’s disease. The findings were published...
